Ascletis Pharma Inc.

Investors

2026

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
2026-03-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
2026-03-03
Voluntary Announcement - Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
2026-02-11
Next Day Disclosure Returns - Others
2026-02-10
Completion of Placing of New Shares under the General Mandate
2026-02-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
2026-02-03
Placing of New Shares under the General Mandate
2026-02-03
Voluntary Announcement - Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
2026-01-29
Voluntary Announcement - Ascletis Announces First Participants Dosed in a 13-Week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
2026-01-26
Voluntary Announcement - Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
2026-01-20

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1